Morgan Stanley Sticks to Its Hold Rating for Alnylam Pharma (ALNY)

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma, with a price target of $360.00.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Ulz is a 2-star analyst with an average return of 0.7% and a 44.38% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Alnylam Pharma, and Sarepta Therapeutics.

In addition to Morgan Stanley, Alnylam Pharma also received a Hold from TipRanks – Google’s Google Biotechnology in a report issued on February 3. However, today, Chardan Capital maintained a Buy rating on Alnylam Pharma (NASDAQ: ALNY).

Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.25 billion and a net profit of $251.08 million. In comparison, last year the company earned a revenue of $500.92 million and had a GAAP net loss of $111.57 million

Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year. Last month, Fitzgerald Kevin Joseph, the CSO & EVP, Head of Research of ALNY sold 1,510.00 shares for a total of $547,927.38.